Skip to main content

Codon Devices to Develop Therapeutic Proteins for Merrimack

NEW YORK (GenomeWeb News) – Codon Devices will work with Merrimack Pharmaceuticals to develop therapeutic proteins under a research, development, and license agreement, Codon said today.
 
Codon will use its BioLogic platform to engineer proteins for specifications set by Merrimack, which is developing therapeutic products aimed at autoimmune disease and cancer.
 
Merrimack will pay Codon clinical milestone payments and royalties on net sales of any protein products that may result from the agreement.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.